ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 16, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 16, 2011
News
FDA Issues Draft Guidance on Nanotechnology
By Amy Ritter
An FDA guidance has provided information for products that involve the application of nanotechnology, and rationales for those points.
Merck to Develop Biosimilar with Korean Chemical Manufacturer
By Patricia Van Arnum
Merck and Hanwha Chemical have formed an exclusive global agreement to develop and a commercialize a biosimilar of Enbrel, a drug to treat moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis.
FDA Reviews First Year of Bad Ad Program
By Erik Greb
After looking back at the first year of its Bad Ad outreach program, FDA judged that the initiative has successfully raised awareness about misleading promotion, according to an FDA press release.
GSK Expands its Vaccine Presence in China
By Stephanie Sutton
GlaxoSmithKline has entered into an agreement to purchase Shenzhen Neptunus? stake in a previously formed joint venture between the companies involved in the development and manufacture of influenza vaccines in China, Hong Kong, and Macau.
Week of June 13, 2011: Company and People Notes: Biogen Idec Receives Approval for the Avonex Pen; Xceleron Makes Several Senior Appointments; and More.
Biogen Idec Receives Approval for the Avonex Pen; Xceleron Makes Several Senior Appointments; and More.
Regulatory Roundup: FDA Takes Action Against Drug Manufacturer and Distributor
FDA Issues Consent Decree of Condemnation, Forfeiture, and Permanent injunction Against H&P Industries, the Triad Group, and Three Individuals.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here